Brand Reference: Androxal (Investigational / 503A Compounded)
| Metric | Verified Benchmark | Source |
|---|---|---|
| Enclomiphene Citrate (Pure Trans-Isomer SERM) RxNorm Concept ID | 1361982 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $1.1500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $165.00 / mo | CMS NADAC + U.S. Retail Markup Index |
| Mark Cuban Cost Plus Wholesale Price | $89.00 / mo (Direct TeleMed) | Direct Telehealth Formulary |
| Community Mean Out-of-Pocket Paid | $95.00 / mo | 39 Zero-PHI Verified Patient Logs |
Isolated trans-stereoisomer of clomiphene (devoid of long-half-life estrogenic cis-zuclomiphene) that blocks estradiol negative feedback on arcuate kisspeptin neurons, amplifying endogenous GnRH, pituitary LH, and FSH pulses to double Leydig-cell testosterone while preserving spermatogenesis.
Classified under Hypothalamic Estrogen Receptor Antagonist / Gonadotropin Secretagogue (Compounded-503A), Enclomiphene Citrate (Pure Trans-Isomer SERM) exhibits a $70.00/month gap between standard U.S. retail cash counters ($165.00) and verified direct-to-patient routing ($95.00) anchored to $1.1500 CMS unit cost.
Pharmacokinetic profiling of Enclomiphene Citrate (Pure Trans-Isomer SERM) demonstrates an elimination half-life of ~10.5 hours (eliminates 30-day zuclomiphene accumulation) with ~85% oral systemic bioavailability; clearance proceeds via hepatic cyp2d6 4-hydroxylation and fecal elimination, reaching clinical onset within 7–14 days serum total/free testosterone doubling.
Titration schedules for Enclomiphene Citrate (Pure Trans-Isomer SERM) (6.25 mg PO once daily → 12.5 mg PO once daily → 25 mg PO once daily) require excluding primary testicular leydig failure (elevated baseline lh > 12); pituitary macroadenoma; history of retinal vein thrombosis; real-world patient logs highlight igf-1 mild suppression (-15%) (18% of reports), mood irritability (9% of reports), transient visual light trails (4% of reports) alongside a 89.80% Worth-It consensus.
Across 39 verified cash-pay logs, Enclomiphene Citrate (Pure Trans-Isomer SERM) achieves a 89.80% Worth-It rating with out-of-pocket spend averaging $95.00/mo versus $165.00/mo walk-in retail.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Switched to Compounding at 6.25 mg PO once daily for Enclomiphene Citrate (Pure Trans-Isomer SERM); monthly out-of-pocket dropped to $83.60 compared with $165.00 retail.
Completed 10 weeks on Enclomiphene Citrate (Pure Trans-Isomer SERM) (12.5 mg PO once daily). Zero notable side effects on steady dosing.
Consistent biomarker response on 25 mg PO once daily Enclomiphene Citrate (Pure Trans-Isomer SERM) sourced via Cost Plus Drugs ($110.20/mo cash pay without insurance prior authorization).